Tacrolimus, a topical calcineurin inhibitor, does not appear to increase the risk of cancer among pediatric patients with atopic dermatitis (AD), according to the findings of a recent study.
Using data from APPLES (A Prospective Pediatric Longitudinal Evaluation to Assess the Long-term Safety of Tacrolimus Ointment for the Treatment of AD), the researchers assessed the incidence of malignancies over 10 years among children with AD treated with topical tacrolimus for 6 weeks or more.
The researchers calculated standardized incidence ratios (SIRs) for cancer events compared with sex-, age-, and race-matched controls using data from national cancer registries. A total of 7954 patients enrolled at 314 sites were included in the study.
Can Calcineurin Inhibitors Effectively Treat Vitiligo?
Boosting the Immune Response as a Treatment for Atopic Dermatitis
The Future of Precision Medicine in the Treatment of Atopic Dermatitis
Six confirmed cancer cases occurred over 44,629 person-years, the researchers said, with no cases of lymphoma diagnosed.
“This finding provides no support for the hypothesis that topical tacrolimus increases long-term cancer risk in children with AD,” the researchers concluded.
Paller AS, Fölster-Holst R, No Chen SC, et al. Evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis [published online April 1, 2020]. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.03.075